Nonalcoholic Steatohepatitis

 Elevated transaminases



• Mainstay of treatment: Management of metabolic conditions




Microscopic




• Steatosis, predominantly macrovesicular
• Lobular inflammation (lymphocytes and Kupffer cells predominates)

• Ballooning

• Both fat and ballooning are most prominent in zone 3

• Mallory-Denk bodies, megamitochondria, glycogenated nuclei

• Fibrosis begins as zone 3 perivenular/pericellular (chicken wire) fibrosis (with exception of pediatric patients); may progress to bridging fibrosis, cirrhosis

• If portal inflammation is accentuated, think of advanced disease or concomitant chronic liver disease

• Nonalcoholic steatohepatitis in pediatric population has different injury pattern

image Inflammation, fibrosis accentuated in portal region

image Ballooning degeneration and perisinusoidal fibrosis not obvious

image
Macrovesicular Steatosis
Macrovesicular steatosis is common in nonalcoholic steatohepatitis (NASH). It frequently begins in zone 3, particularly in adults, and may extend to become panzonal.


image
Hepatocyte Ballooning
Ballooned hepatocytes image are common in NASH and may be associated with Mallory-Denk bodies. Note the steatosis and glycogenated nuclei as well.

image
Pericellular Fibrosis
Trichrome stain highlights the pericellular fibrosis that is typical of steatohepatitis and NASH. In adults, the fibrosis typically begins in zone 3.

image
Glycogenated Nuclei
Glycogenated nuclei image, featuring clear, vesicular nuclei within hepatocytes, are a common, but nonspecific, finding in NASH.


TERMINOLOGY


Abbreviations




• Nonalcoholic steatohepatitis (NASH)


Definitions




• Steatosis, inflammation, and ballooning in absence of history of alcohol use


ETIOLOGY/PATHOGENESIS


Mechanism




• Hepatic accumulation of lipids provides source of oxidative stress and leads to injury/inflammation

• Subsequent activation of TGF-β and hepatic stellate cells results in fibrosis


Associated Conditions




• Metabolic syndrome, drugs, malabsorption, malnutrition


CLINICAL ISSUES


Presentation




• Hepatomegaly

• Metabolic syndrome, including central obesity, type 2 diabetes, dyslipidemia, hypertension


Laboratory Tests




• Elevated transaminases


Treatment




• Management of associated metabolic syndrome

• Many drugs under investigation


Prognosis




• May progress to fibrosis, cirrhosis, and hepatocellular carcinoma

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Apr 20, 2017 | Posted by in PATHOLOGY & LABORATORY MEDICINE | Comments Off on Nonalcoholic Steatohepatitis

Full access? Get Clinical Tree

Get Clinical Tree app for offline access